Form D · Pharmaceuticals
ALIOS BIOPHARMA INC
South San Francisco, CA · CIK 0001380990
Offering snapshot reported May 19, 2014 · SEC filing
- Reported sold
- $41M Offering amount: $41M
- Investors reported
- 14 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 2, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 19, 2014 | Initial | $41,000,001 | No comparison | 14 | SEC filing |
| Jan 29, 2010 | Amendment | $30,241,356 | $19,200,000vs Jun 19, 2009 | 18 | SEC filing |
| Jun 19, 2009 | Amendment | $11,041,356 | No comparison | 18 | SEC filing |
| Jan 27, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Oct 31, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-217630
Source: Form D, filed May 19, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Leonid Beigelman | Executive |
| Lawrence Blatt | Director, Executive |
| John Donovan | Executive |
| Jens Eckstein | Director |
| Kent Gossett | Director |
| Peter Hirth | Director |
| Campbell Murray | Director |
| Jack Nielsen | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
260 East Grand Avenue, 2 Nd Floor
South San Francisco, CA, 94080
South San Francisco, CA, 94080